Publications and Presentations
Learn more about our scientific and clinical research.
2025
ASH
- Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate Manufactured from CD62L+ Enriched T Cells, Achieves Durable Responses in Patients with Large B-Cell Lymphoma
- CD62L Enrichment Achieves Robust Expansion and Memory Phenotype Post-Infusion in Patients with LBCL Treated with Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate
International Conference on Malignant Lymphoma
2024
AACR
SITC
- Multiomic Profiling of LYL119: Reprogramming ROR1 CAR T cells With Reduced Exhaustion and Enhanced Memory Characteristics Is Associated With Increased AP-1 and ReducedNR4A Binding
- LYL797 Reprogrammed ROR-1 CAR T cells Demonstrate Limited Exhaustion, Maintenance of Stemness and Tumor Infiltration with Evidence of Tumor Lysis in Patients with Solid Tumors
- Utilizing Stim-R™ Technology to Reduce Irradiated Feeder Cell Use in the Tumor Infiltrating Lymphocyte Culture Process
2023
SITC
- Epi-R™ P2 Protocol Produces a Scalable Polyclonal TIL Product With a Greater Expansion Success Rate Across Hot and Cold Tumors in Shorter Culture Time
- Preclinical Development of LYL119, a ROR1-Targeted CAR T-Cell Product Candidate Incorporating Four Novel T-Cell Reprogramming Technologies to Overcome Barriers to Effective Cell Therapy for Solid Tumors
- Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T-cell therapies
- Rejuvenation of Tumor-Infiltrating Lymphocytes (TIL) Through Partial Reprogramming
- Phase 1 Trial of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced With Genetic and Epigenetic Reprogramming, in Advanced Triple-Negative Breast Cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC)
- Phase 1 Trial of LYL845, an Autologous Tumor-Infiltrating Lymphocyte (TIL) Therapy Enhanced With Epigenetic Reprogramming for the Treatment of Advanced Solid Tumors
2022
ASGCT
- Epigenetic reprogramming (Epi-R™) yields an NY-ESO-1 T-cell receptor product (LYL132; GSK4427296) with improved stemness, metabolic fitness, and functional activity in the presence of persistent antigen exposure
- Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors
SITC
- NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo
- Epi-R™ Technology Produces a Polyclonal TIL Product (LYL845) With Diverse Tumor-Reactive Clones That Have Stem-Like Qualities and Anti-Tumor Function
- Epi-R™ Technology Produces a Polyclonal TIL Product (LYL845) With a Greater Expansion Success Rate Across Hot and Cold Tumors, Improved Product Phenotype, and Maintenance of TCR Diversity
- Engineering Potent CAR T-Cell Therapies by Controlling T-Cell Activation Signaling Parameters Using the Stim-R™ Technology, a Programmable Synthetic Cell-Signaling Platform
- Increased Potency and Functional Persistence in vitro of a Next-Generation NY-ESO-1—specific TCR Therapy Incorporating Gen-R™ Genetic Reprogramming Technology